Our Process
An Innovative Model for Bringing Therapies to Japan
DLR Pharma transforms promising global therapies into real-world solutions for Japanese patients through a streamlined, strategic process. Our integrated model makes it possible for international biotechs and pharma companies to bring therapies to Japan without the usual barriers:
Drug Scouting
We identify high-potential drugs that haven’t yet reached Japan—especially those with strong clinical promise but limited market access.
Business Case Development
We craft robust business strategies—complete with market forecasts, development plans, and financial modeling—to support each opportunity and attract investment.
Investor-Backed Licensing
With investor backing, we license these therapies and fund their development through our own Japanese subsidiary.
Clinical Development in Japan
Our team navigates the regulatory landscape and runs trials tailored to Japanese standards and patient needs.
Strategic Exit or Partnership
Once ready, we partner with leading Japanese pharma companies to bring these therapies to reach patients nationwide —either through strategic sale or collaboration.
The result: life-changing treatments, delivered faster, with less risk, and with a clear path to market.